Table 2.
Jejunal and ileal neuroendocrine tumors treatment
Jejunal and ileal NETs – surgical treatment | |
Without metastasis, all sizes | Surgical resection with wide lymphadenectomy + search for other lesions |
With liver metastases | Attempt curative surgery; intraoperative ultrasonography should be performed for detection of all liver metastases |
If patient not suitable for curative resection, palliative surgery should be considered to prevent complications attributable to the tumor mass | |
Jejunal and ileal NETs – farmacological treatment | |
Functional jejunal-ileal NETs | 1st line: Somatostatin analogs (symptomatic treatment and tumor growth stabilization) |
2nd line: Interferon-α | |
Well-differentiated NETs | Systemic chemotherapy not recommended |
Poorly differentiated tumors | Combination chemotherapy – variable duration disease remission |
mTOR, tyrosine kinase and VEGF inhibitors – phase 3 trials with promising results | |
Metastatic or inoperable disease | Peptide receptor radionuclide therapy |
When all other treatment options fail | |
If positive Octreoscan |
NETs: Neuroendocrine tumors; VEGF: Vascular endothelial growth factor.